TENAYA THERAPEUTICS, INC. TNYA 深 滬
已收盤 09-05 16:00:00 美东时间
1.35
+0.110
+8.87%
華盛通- 最 高1.37
- 今 開1.26
- 成交量 462.63万股
- 最 低 1.26
- 昨 收 1.24
- 總市值 2.20亿
- 52周最高 4.01
- 市盈率 靜 --
- 換手率 2.84%
- 52周最低 0.36
- 委 比 72.83%
- 總股本 1.63亿
- 歷史最高 32.00
- 量 比 1.63
- 振 幅 8.87%
- 歷史最低 0.36
- 每 手 1
- 風險率 1.28%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Tenaya Therapeutics to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
Tenaya Therapeutics' CEO, Faraz Ali, will participate in a fireside chat at Morgan Stanley's 23rd Annual Global Healthcare Conference on September 9, 2025. The event will be webcast live and available for replay on Tenaya's website. Tenaya focuses on developing curative therapies for heart disease, with a pipeline including gene therapies TN-201 and TN-401, and small molecule HDAC6 inhibitor TN-301. For more details, visit their website or contac...
09-02 20:05
Tenaya Therapeutics Presents Interim Data from MyClimb™ Natural History Study of MYBPC3-associated HCM Pediatric Patients at European Society of Cardiology Congress 2025
Tenaya Therapeutics presented interim data from its MyClimb study, the largest noninterventional natural history study of pediatric participants with MYBPC3-associated hypertrophic cardiomyopathy (HCM), at the European Society of Cardiology Congress. The study highlights the severe risks and rapid progression of the disease, particularly in nonobstructive HCM, which lacks approved treatments. Key findings include: 93% of participants had nonobstr...
08-31 14:15
HC Wainwright & Co. Reiterates Buy on Tenaya Therapeutics, Maintains $5 Price Target
HC Wainwright & Co. analyst Joseph Pantginis reiterates Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and maintains $5 price target.
08-27 18:15
Analysts’ Top Healthcare Picks: Tenaya Therapeutics (TNYA), Nexalin Technology, Inc. (NXL)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
08-21 17:03
Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
Tenaya Therapeutics' CEO, Faraz Ali, will speak at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025. The event will be webcast live and available via the Investors section of Tenaya's website, with an archive for 30 days. Tenaya focuses on developing curative therapies for heart diseases, with clinical-stage candidates TN-201 and TN-401 targeting genetic cardiomyopathies. The company leverages genetic insights and innovative...
08-08 12:00
Chardan Capital Maintains Buy on Tenaya Therapeutics, Maintains $9 Price Target
Chardan Capital analyst Geulah Livshits maintains Tenaya Therapeutics (NASDAQ:TNYA) with a Buy and maintains $9 price target.
08-07 20:50
Tenaya Therapeutics Q2 EPS $(0.14) Beats $(0.17) Estimate
Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.17) by 17.65 percent. This is a 58.82 percent increase over losses of $(0.34) per share
08-07 05:13
Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Tenaya Therapeutics announced the completion of enrollment and positive safety reviews for its gene therapy trials for MYBPC3-associated hypertrophic cardiomyopathy (HCM) and PKP2-associated arrhythmogenic right ventricular cardiomyopathy (ARVC). The Data Safety Monitoring Board recommended dose escalation and expansion for both TN-201 and TN-401 trials, with initial data expected in the fourth quarter of 2025. The company reported a cash runway ...
08-06 20:30
Tenaya Therapeutics Completes Enrollment In MyPEAK-1 Trial For HCM And Initiates RIDGE-1 Trial For ARVC With DSMB Endorsements
Enrollment in Both Dose Cohorts of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Hypertrophic Cardiomyopathy (HCM) Complete; Follow-up Data from Cohort 1 and Initial Data from Cohort 2 Expected
07-30 20:36
Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed
Tenaya Therapeutics announced positive endorsements from independent Data Safety and Monitoring Boards (DSMBs) for its MyPEAK-1 (TN-201) and RIDGE-1 (TN-401) gene therapy clinical trials targeting hypertrophic cardiomyopathy (HCM) and arrhythmogenic right ventricular cardiomyopathy (ARVC), respectively. Both trials were granted approval to proceed as planned. Initial data from Cohort 1 of MyPEAK-1 showed promising results, including improved card...
07-30 12:30
